| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H21ClFN3O4S |
| Molecular Weight | 441.904 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(NC(=O)NC2=C(O)C(=C(Cl)C=C2)S(=O)(=O)[C@H]3CCCNC3)C=CC=C1F
InChI
InChIKey=NGYNBSHYFOFVLS-LBPRGKRZSA-N
InChI=1S/C19H21ClFN3O4S/c1-11-14(21)5-2-6-15(11)23-19(26)24-16-8-7-13(20)18(17(16)25)29(27,28)12-4-3-9-22-10-12/h2,5-8,12,22,25H,3-4,9-10H2,1H3,(H2,23,24,26)/t12-/m0/s1
| Molecular Formula | C19H21ClFN3O4S |
| Molecular Weight | 441.904 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Danixirin is a potent, competitive, selective and reversible antagonist of the chemokine receptor (CXCR2) (also known as interleukin 8B receptor). In preclinical models, danixirin blocked neutrophils chemotaxis in response to inflammation. The drug is being developed by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease, influenza, respiratory syncytial virus. In phase 2 clinical trials in patients with acute, uncomplicated influenza, danixirin was well tolerated and did not impede viral clearance.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 7.9 null [pIC50] |
